IVIG (intravenous immunoglobulin) can cause liver damage, though the injury is usually mild and temporary. The most common pattern involves a rise in liver enzymes during or shortly after infusion, which typically resolves once treatment stops. In rare cases, the damage can be more severe, and the history of IVIG includes a darker chapter involving hepatitis C contamination that caused serious, sometimes fatal, liver disease in the 1980s. Understanding the distinction between these scenarios matters for anyone receiving IVIG or weighing its risks.
The Typical Pattern Is a Temporary Rise in Liver Enzymes
The liver effect most commonly associated with IVIG is what clinicians call transaminitis, a rise in the enzymes ALT and AST that the liver releases when its cells are stressed or damaged. For most patients, this enzyme bump appears during or shortly after an IVIG infusion course and comes back down on its own without any specific treatment. The rise can look alarming on a lab printout, but it does not usually mean the liver is sustaining lasting harm.
Case reports and small series have consistently noted this transient quality. One review of available evidence found that with cessation of IVIG, liver enzyme elevations resolved both in the patients studied and in previously reported cases, and the authors noted they had not encountered a fatal or disabling case of liver injury from IVIG’s direct effect on the liver.1PubMed Central. Intravenous Immunoglobulin Induced Transaminitis That is a reassuring baseline, but it does not mean the problem is always trivial or that no patient has experienced something worse.
Why Stabilizers May Be Part of the Problem
IVIG is not just purified antibodies in a bag. The final product contains stabilizing agents added during manufacturing to keep the immunoglobulin molecules from clumping or degrading. Different brands use different stabilizers, and some of these additives appear to contribute to liver enzyme elevations. A case series examining IVIG-associated liver enzyme rises in patients with neurological autoimmune conditions pointed to the stabilizing agent maltose as a likely factor.2PubMed Central. Intravenous Immunoglobulin-Associated Elevation of Liver Enzymes in Neurological Autoimmune Disorder: A Case Series While the enzyme elevations in that series were self-limiting, the finding raises a practical question: could switching to a differently formulated product reduce the risk for a given patient?
Common IVIG stabilizers include sucrose, glycine, proline, and maltose, and they vary by manufacturer. Sucrose, for instance, has been more closely linked to kidney problems than liver ones, while maltose has appeared in liver-related case reports. If you develop liver enzyme elevations on one IVIG brand, your doctor may try a product with a different stabilizer before concluding that IVIG itself is the culprit. This is not always discussed upfront, but it is a recognized approach in clinical practice.
When Liver Injury Goes Beyond Mild
Though most IVIG-associated liver effects are self-limiting, there are documented cases where the damage is more than a transient enzyme blip. A particularly striking case involved a 33-year-old woman receiving repeated IVIG infusions during pregnancy to prevent a recurrence of gestational alloimmune liver disease in her unborn twins. She developed jaundice and acute hepatitis, and a liver biopsy showed hepatocellular injury with bridging necrosis and cholestatic features consistent with drug-induced liver injury.3PubMed Central. Drug-induced Liver Injury from Intravenous Immunoglobulin for Prevention of Recurrent Gestational Alloimmune Liver Disease: A Clinical Catch-22 Bridging necrosis is not a minor finding. It means bands of dead liver cells stretching across zones of the liver tissue, a pattern that in other drug-injury contexts can precede liver failure if it progresses.
This case is instructive for several reasons. The patient was receiving high cumulative doses of IVIG over multiple infusions, not just a one-time treatment. She was also pregnant, which changes how the liver handles drug metabolism. And the condition she was being treated for, gestational alloimmune liver disease, itself affects the liver, creating a diagnostic puzzle. Was the liver damage from IVIG, from the underlying disease flaring, or from both? The biopsy findings pointed toward drug-induced injury, but the clinical scenario illustrates why sorting out IVIG-related liver damage from other causes can be genuinely difficult.
The Hepatitis C Chapter
Any discussion of IVIG and liver damage has to reckon with history. In the 1980s, before the hepatitis C virus was even identified as a distinct pathogen, multiple outbreaks of what was then called non-A, non-B hepatitis were traced to contaminated IVIG products. This was not a subtle drug side effect. It was a viral infection transmitted through pooled human plasma.
One study from that era documented the scale of the problem in a particularly vulnerable group. Among 77 patients with common variable immunodeficiency or IgG subclass deficiency receiving IVIG, 16 (about 21 percent) contracted non-A, non-B hepatitis. Twelve of those patients had clinical symptoms, and five died, with hepatitis as the cause of death in two and a contributing factor in three. Liver biopsies showed early chronic active hepatitis and cirrhosis.4The American Journal of Medicine. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency The hepatitis appeared to run a more severe course in these immunodeficient patients than in people with intact immune systems, which makes biological sense: their ability to control the virus was already compromised.
Once the hepatitis C virus was identified and testing became available, the picture clarified. Investigations showed that cold ethanol fractionation, the standard step in IVIG manufacturing, was important for viral safety. Two episodes of hepatitis C transmission through anti-D immune globulin preparations were linked to products manufactured without that fractionation step. Other outbreaks were associated with additional chromatography steps that may have inadvertently concentrated the virus rather than removing it.5PubMed. The viral safety of intravenous immune globulin The observation that all IVIG products linked to hepatitis C transmission had been freeze-dried raised the possibility that lyophilization was stabilizing the virus in the final product.
The response was sweeping. Manufacturers began screening all plasma donors for anti-hepatitis C antibodies and introduced specific antiviral steps into production, including solvent-detergent treatment and low-pH incubation. A review of IVIG adverse effects noted that these measures, combined with excluding seropositive donors, should prevent further outbreaks.6SpringerLink. Adverse effects of intravenous immunoglobulin And by the evidence available decades later, they largely have. Modern IVIG products carry an extremely low risk of transmitting hepatitis C or other blood-borne viruses. But the history explains why older medical literature sometimes presents IVIG and liver disease as a more alarming combination than current experience warrants.
Who Faces Higher Risk
Not everyone receiving IVIG has the same likelihood of developing liver problems. Several factors appear to increase vulnerability, though the evidence is drawn more from case reports and clinical observation than from large controlled trials.
- Immunodeficient patients: As the 1980s hepatitis C data showed, people with primary immunodeficiency disorders were disproportionately affected by viral transmission through IVIG and had worse outcomes when infected. Even setting aside the historical contamination issue, these patients often receive IVIG chronically, month after month, increasing cumulative exposure.
- High or repeated dosing: A single low-dose infusion carries less liver risk than the high-dose regimens used for autoimmune conditions like Kawasaki disease, immune thrombocytopenia, or Guillain-Barré syndrome, where doses can reach 2 grams per kilogram of body weight over a few days. Repeated high-dose courses, as in the pregnancy case described above, multiply the exposure further.
- Pre-existing liver disease: Patients who already have compromised liver function from any cause, whether fatty liver disease, chronic hepatitis, or alcohol-related damage, have less hepatic reserve to absorb the added stress of IVIG and its excipients.
- Pregnancy: Pregnancy alters liver metabolism and blood flow, and conditions that call for IVIG during pregnancy sometimes involve the liver directly, creating overlapping risks.
None of these factors make IVIG categorically unsafe. They mean monitoring should be more frequent and that early signs of liver irritation deserve a faster response.
What Monitoring Looks Like in Practice
Because liver enzyme elevations are a known risk, many clinicians order baseline liver function tests before starting IVIG and check them periodically during treatment, especially during early infusions when you do not yet know how a particular patient will respond. If ALT or AST levels start climbing, the decision tree branches depending on severity.
A modest rise, say two to three times the upper limit of normal, with no symptoms and no rise in bilirubin, often leads to watchful waiting. The next infusion may proceed with closer monitoring. A more dramatic spike, particularly if accompanied by jaundice, fatigue, nausea, or dark urine, typically triggers a pause in IVIG while other causes of liver injury are ruled out. That workup generally includes screening for viral hepatitis, checking for autoimmune hepatitis (which can mimic drug-induced injury and, confusingly, is sometimes the very condition IVIG was prescribed to treat), reviewing other medications the patient takes, and imaging the liver and biliary system to exclude obstruction.
The case report involving bridging necrosis underscored the value of close clinical monitoring during IVIG therapy and the need for further research into alternatives when IVIG itself may be harming the organ it is meant to protect.3PubMed Central. Drug-induced Liver Injury from Intravenous Immunoglobulin for Prevention of Recurrent Gestational Alloimmune Liver Disease: A Clinical Catch-22 In practice, this means that if you are on IVIG and your liver numbers are rising, the conversation with your doctor should include whether a different IVIG formulation, a dose adjustment, or an alternative therapy altogether makes more sense going forward.
Why the Mechanism Is Still Not Fully Understood
Given how long IVIG has been in use, it is somewhat surprising that the exact way it injures the liver remains unclear. With most drugs, the mechanism of hepatotoxicity falls into a few recognized categories: the drug itself is directly toxic to liver cells, or the liver’s attempt to metabolize the drug produces a toxic byproduct, or the immune system mounts a reaction against liver cells that have been altered by the drug. IVIG is unusual because it is not a small-molecule drug. It is a pooled mix of thousands of human antibodies, plus stabilizers, and the sheer complexity of the product makes it hard to pinpoint which component is doing the harm and how.
Some researchers have pointed to the stabilizers, as discussed earlier. Others have speculated that certain IgG subclasses or aggregates within the product may activate immune pathways in the liver. Still others note that the massive protein load delivered during high-dose infusions could itself stress the liver’s processing capacity. The honest answer is that no single mechanism has been confirmed, and it may vary by patient and product. As one review put it, the failure to completely understand the underlying disease process is notable, but the consistent observation is that the injury resolves when IVIG stops.1PubMed Central. Intravenous Immunoglobulin Induced Transaminitis
This gap in understanding has practical consequences. Without knowing the mechanism, it is hard to predict which patients will develop liver problems, hard to design IVIG products that avoid the issue, and hard to develop targeted interventions beyond stopping the drug. Liver biopsy could provide more clues, but because the injury is almost always self-resolving, there has been little justification for subjecting patients to an invasive procedure purely for research purposes.
Hemolysis and the Liver Enzyme Red Herring
There is a related phenomenon that can create confusion on lab work. IVIG is well known to cause hemolysis, the destruction of red blood cells, in some patients. This happens because pooled immunoglobulin contains anti-A and anti-B antibodies that can attack the recipient’s red blood cells if blood types do not align perfectly. When red blood cells break apart, they release their contents into the bloodstream, and one of those contents is lactate dehydrogenase (LDH), an enzyme that also comes from the liver.
A patient experiencing IVIG-related hemolysis may show elevated LDH and indirect bilirubin on blood work, and if the clinician is not thinking about hemolysis, those numbers might initially look like liver damage. The distinction matters because the treatment response is completely different. True drug-induced liver injury calls for stopping or changing the IVIG. Hemolysis calls for monitoring, possibly transfusion support, and sometimes a change in IVIG product or pre-medication strategy, but it is a blood problem, not a liver problem. Checking a direct-versus-indirect bilirubin split and a reticulocyte count usually sorts this out quickly.
Modern IVIG Safety Compared to Early Products
If you are reading about IVIG and liver damage today, much of the most alarming data comes from the 1980s, before hepatitis C was identified and before modern manufacturing safeguards were in place. The landscape has changed considerably. Current IVIG products undergo multiple viral inactivation and removal steps during manufacturing, including nanofiltration, solvent-detergent treatment, and low-pH incubation. Plasma donors are screened with nucleic acid testing that can detect viral genetic material even before antibodies develop, closing the window period that allowed contaminated plasma to slip through in earlier decades.
The result is that virus transmission through modern IVIG is vanishingly rare. The liver risks that remain are the direct drug-related effects: the transient enzyme elevations, the occasional more severe hepatocellular injury, and the stabilizer-related reactions. These are real but manageable risks, not the catastrophic contamination events of the past. For patients who need IVIG, whether for primary immunodeficiency, autoimmune disease, or acute inflammatory conditions, the benefit-risk calculation almost always favors treatment, with appropriate liver monitoring built into the care plan.